Sage Therapeutics has announced the discontinuation of dalzanemdor development following its failure in a Phase II clinical trial for Huntington's disease. This setback marks the third unsuccessful indication for the NMDA modulator, significantly impacting Sage's pipeline prospects. The company now focuses on its one commercial drug and three early-stage assets.
The Phase II trial aimed to assess the efficacy and safety of dalzanemdor in patients with Huntington's disease. However, the drug did not meet its primary or secondary endpoints, leading to the decision to halt further development. This outcome follows other negative readouts from Sage's planned 2024 clinical trials.
The failure of dalzanemdor in Huntington's disease represents a significant blow to Sage's R&D efforts, as it was a key asset in their mid-stage pipeline. The company will now need to reassess its strategy and prioritize its remaining assets.
